|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅰ safety and pharmacokinetic study of recombinat human antivascular endothelial growth factor in patients with advanced cancer 显示文摘 | Gordon MS Margolin K Talpaz M | 2001 | J Clin Oncol2001，19，4： | 1 |
| 2 | Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors显示文摘 | Gordon MS Sweeney CS Mendelson DS | 2010 | Clin Cancer Res2010，16，2： | 1 |
| 3 | Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation 显示文摘 | Singhal S Gordon LI Tallman MS | 2006 | Bone Marrow Transplant2006，37，11： | 1 |
| 4 | Phase U trial of 2-chlorodeoxyadenosine in patients with relapsed/ refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995显示文摘 | Gordon MS Young ML Tallman MS | 2000 | Leuk Res2000，24，10： | 1 |
| 5 | Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth显示文摘 | Chen H Gordon MS Campbell RA | 2007 | Blood2007，110，1： | 1 |
| 6 | Combination of trastuzumab and tanespimycin (17-AAG,KOS -953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer:a phase Ⅰ dose-escalation study显示文摘 | Modi S Stopeck AT Gordon MS | 2007 | J Clin Oncol2007，25，： | 1 |
| 7 | Simulation and new learning technologies显示文摘 | Issenberg SB Gordon MS Gordon DL | 2001 | Med Teach2001，23，： | 1 |
| 8 | Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer显示文摘 | Gordon MS Margolin K Talpaz M | | 0，，： | 1 |
| 9 | Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer 显示文摘 | Gordon MS Margolin K Talpaz M | 2001 | J Clin Oncol2001，19，3： | 1 |
| 10 | In vivo administration of recombinant methionyl human stem cell faetor expands the number of human marrow hematopoietic stem cells显示文摘 | Tong J Gordon MS Srour EF | 1993 | Blood1993，82，3： | 1 |
| 11 | Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients advanced cancer显示文摘 | Gordon MS Margolin K Talpaz M | 2001 | Clin Oncol2001，19，： | 1 |
| 12 | Safety, pharmaco- kinetics, and pharmacodynamics of AMG 102, a fully human hepa- tocyte growth factor-neutralizing monoclonal antibody, in a first- in-human study of patients with advanced solid tumors 显示文摘 | Gordon MS Sweeney CS Mendelson DS | 2012 | Cliu Cancer Res2012，16，2： | 1 |
| 13 | Novel antiangiogenic therapies for renal cell cancer显示文摘 | Gordon MS | 2004 | Clin Cancer Res2004，10，182： | 1 |
| 14 | Bedside cardiology skills training for the osteopathic internist using simulation technology显示文摘 | Issenberg SB Gordon MS Greber AA | | 0，，12： | 1 |
| 15 | Tumor angiogen- esis and novel antiangiogenic strategies 显示文摘 | Gordon MS Mendelson DS Kato G | 2010 | Int J Cancer2010，126，8： | 1 |
| 16 | A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11growth factor) in woman with breast cancer receiving chemotherapy显示文摘 | Gordon MS McCaskill-Stevens WJ Battiato LA | 1996 | Blood1996，87，： | 1 |
| 17 | A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy显示文摘 | Gordon MS MeCaskill-Stevens WJ Battiato LA | 1996 | Blood1996，87，9： | 1 |
| 18 | A phase I trial of recombinant human interleukin-11(neumega rhIL-11 growth factor) in women wi th breast cancer receiving chemotherapy显示文摘 | GORDON MS McCASKILL-STEVENS WJ BATTIATO LA | 1996 | Blood1996，87，9： | 1 |
| 19 | Dynamic digital traction for unstable comminutcd intra articalar fracture dislocation of the proximal into erphalangeal joint 显示文摘 | Morgan JP Gordon DA Klug MS ct al | 1995 | J Hand Surg1995，20，4： | 1 |
| 20 | Comparisons of treatment optimization directly incorporating random patient setup uncertainty with a margin-based approach 显示文摘 | Moore JA Gordon JJ Anscher MS | 2009 | Med Phys2009，36，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员